Last reviewed · How we verify
Egrifta (TESAMORELIN ACETATE)
Egrifta (generic name: TESAMORELIN ACETATE) is a Growth Hormone Releasing Factor Analog Recombinant protein drug developed by Theratechnologies. It is currently FDA-approved (first approved 2010) for Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy.
Egrifta works by mimicking the action of growth hormone-releasing hormone to stimulate the release of growth hormone.
Egrifta, also known as tesamorelin, is a growth hormone-releasing hormone receptor agonist that belongs to the drug class of agonists. It is used to treat Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, and Hepatic Steatosis.
At a glance
| Generic name | TESAMORELIN ACETATE |
|---|---|
| Sponsor | Theratechnologies |
| Drug class | Growth Hormone Releasing Factor Analog |
| Target | Growth hormone-releasing hormone receptor |
| Modality | Recombinant protein |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2010 |
Mechanism of action
Think of it like a key that unlocks a door. Growth hormone-releasing hormone is the key, and Egrifta is a copy of that key. When Egrifta is given, it fits into the lock and tells the body to release more growth hormone, which helps to reduce fat accumulation in the body.
Approved indications
- Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy
Common side effects
- Product dose omission issue
- Product administration error
- Injection site bruising
- Injection site pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Egrifta CI brief — competitive landscape report
- Egrifta updates RSS · CI watch RSS
- Theratechnologies portfolio CI
Frequently asked questions about Egrifta
What is Egrifta?
How does Egrifta work?
What is Egrifta used for?
Who makes Egrifta?
What is the generic name of Egrifta?
What drug class is Egrifta in?
When was Egrifta approved?
What development phase is Egrifta in?
What are the side effects of Egrifta?
What does Egrifta target?
Related
- Drug class: All Growth Hormone Releasing Factor Analog drugs
- Target: All drugs targeting Growth hormone-releasing hormone receptor
- Manufacturer: Theratechnologies — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing